Institute of Translational Medicine, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom of Great Britain.
Overcoming cancer drug resistance research unit, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Planta Med. 2022 Feb;88(2):163-178. doi: 10.1055/a-1307-3997. Epub 2021 Jan 14.
Estrogen receptor-positive breast cancer patients have a good prognosis, but 30% of these patients will experience recurrence due to the development of resistance through various signaling pathways. This study aimed to evaluate the mode of anticancer effects of 1'-acetoxychavicol acetate, which is isolated from the rhizomes of in estrogen receptor positive (MCF7) human epidermal growth factor receptor 2-overexpressed (MCF7/HER2), and endocrine-resistant breast cancer cells (MCF7/LCC2 and MCF7/LCC9). 1'-Acetoxychavicol acetate showed antiproliferation in a concentration- and time-dependent fashion and had higher potency in human epidermal growth factor receptor 2-overexpressed cell lines. This was associated with down-regulation of human epidermal growth factor receptor 2, pERK1/2, pAKT, estrogen receptor coactivator, cyclin D1, and MYC proto-oncogene while and significant reduction in the tumor mass of 1'-acetoxychavicol acetate-treated zebrafish-engrafted breast cancer groups. The anti-invasive effects of 1'-acetoxychavicol acetate were confirmed by the matrigel invasion assay and with down-regulation of C - X-C chemokine receptor type 4, urokinase plasminogen activator, vascular endothelial growth factor, and basic fibroblast growth factor 2 genes. The down-regulation of urokinase plasminogen activator and fibroblast growth factor 2 proteins was also validated by molecular docking analysis. Moreover, 1'-acetoxychavicol acetate-treated cells exhibited lower expression levels of the anti-apoptotic Bcl-2 and Mcl-1 proteins in addition to enhanced stress-activated kinases/c-Jun N-terminal kinase 1/2 and poly-ADP ribose polymerase cleavage, indicating apoptotic cell induction by 1'-acetoxychavicol acetate. Moreover, 1'-acetoxychavicol acetate had higher potency in human epidermal growth factor receptor 2-overexpressed cell lines regarding its inhibition on human epidermal growth factor receptor 2, pAKT, pERK1/2, PSer, and PSer-ER proteins. Our findings suggest 1'-acetoxychavicol acetate mediates its anti-cancer effects via human epidermal growth factor receptor 2 signaling pathway.
雌激素受体阳性乳腺癌患者预后良好,但其中 30%的患者会因通过各种信号通路产生耐药性而复发。本研究旨在评估 1'-乙酰氧基胡椒酚乙酸酯对雌激素受体阳性(MCF7)人表皮生长因子受体 2 过表达(MCF7/HER2)、内分泌耐药乳腺癌细胞(MCF7/LCC2 和 MCF7/LCC9)的抗癌作用模式。1'-乙酰氧基胡椒酚乙酸酯呈浓度和时间依赖性的增殖抑制作用,对人表皮生长因子受体 2 过表达细胞系的活性更高。这与表皮生长因子受体 2、pERK1/2、pAKT、雌激素受体共激活剂、细胞周期蛋白 D1 和 MYC 原癌基因下调以及 1'-乙酰氧基胡椒酚乙酸酯处理的斑马鱼植入乳腺癌组肿瘤质量显著降低有关。1'-乙酰氧基胡椒酚乙酸酯的抗侵袭作用通过基质胶侵袭试验得到证实,并伴有 C-X-C 趋化因子受体 4、尿激酶纤溶酶原激活物、血管内皮生长因子和碱性成纤维细胞生长因子 2 基因下调。尿激酶纤溶酶原激活物和成纤维细胞生长因子 2 蛋白的下调也通过分子对接分析得到验证。此外,1'-乙酰氧基胡椒酚乙酸酯处理的细胞还表现出较低的抗凋亡 Bcl-2 和 Mcl-1 蛋白表达水平,同时增强应激激活激酶/c-Jun N-末端激酶 1/2 和多聚 ADP 核糖聚合酶裂解,表明 1'-乙酰氧基胡椒酚乙酸酯诱导细胞凋亡。此外,1'-乙酰氧基胡椒酚乙酸酯在人表皮生长因子受体 2 过表达细胞系中对人表皮生长因子受体 2、pAKT、pERK1/2、PSer 和 PSer-ER 蛋白的抑制作用更强。我们的研究结果表明,1'-乙酰氧基胡椒酚乙酸酯通过人表皮生长因子受体 2 信号通路介导其抗癌作用。